Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.

@article{Molina2014SunitinibOR,
  title={Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.},
  author={Ana Mar{\'i}a Pe{\~n}a Molina and Xun Lin and Beata Korytowsky and Ewa Matczak and Mariajos{\'e} Lechuga and Robin Wiltshire and Robert J Motzer},
  journal={European journal of cancer},
  year={2014},
  volume={50 2},
  pages={
          351-8
        }
}
BACKGROUND Retrospective analyses were performed in patients with metastatic renal cell carcinoma (mRCC) to characterise the objective response (OR) rate to sunitinib and differentiate pretreatment features and outcomes of patients with early (response by ≤ 12 weeks) versus late response, and responders versus non-responders. METHODS Data were pooled from 1059 patients in six trials. Median progression-free survival (PFS) and overall survival (OS) were estimated by Brookmeyer and Crowley… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Extracellular vesicles and anti-cancer drug resistance.

  • Biochimica et biophysica acta. Reviews on cancer
  • 2018
VIEW 1 EXCERPT
CITES RESULTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Early primary tumor size reduction is an independent predictor of Please cite this article in press

EJ Abel, SH Culp, +3 authors CG. Wood
  • Eur J Cancer
  • 2013

Novel oncologic drugs: what they do and how they affect images.

  • Radiographics : a review publication of the Radiological Society of North America, Inc
  • 2011
VIEW 2 EXCERPTS